XKRX
137310
Market cap773mUSD
Apr 29, Last price
9,410.00KRW
1D
1.95%
1Q
-18.88%
IPO
-84.08%
Name
SD Biosensor Inc
Chart & Performance
P/E
—
P/S
1.60
EPS
—
Div Yield, %
—
Shrs. gr., 5y
3.54%
Rev. gr., 5y
56.94%
Revenues
694.57b
+5.93%
Net income
-98.41b
L-78.96%
CFO
156.53b
P
Dividend
Dec 27, 2023290 KRW/sh
Profile
SD BioSensor Inc., an in-vitro diagnostic company, provides point-of-care diagnostic solutions in South Korea and internationally. The company's products include STANDARD Q, which provides various rapid test parameters comprising COVID-19 products and other parameters; STANDARD F, a multi-parametric and random accessible FIA system that provides diagnostic results to the laboratories; and STANDARD E, an enzyme linked immunosorbent assay for mass screening tests. Its products also include STANDARD M, a point-of-care MDx system for clinical decision making near-the-patient, which include analyzers, assay menus, qPCR reagents, and NA extraction kits; procell Dx, an in vitro diagnostic products for the diagnosis of infectious disease, such as tuberculosis and SARS-CoV-2, and for checking the immune status of individuals through the interferon gamma release assay; and blood glucose meters. The company was founded in 2010 and is headquartered in Suwon, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | |||||||
Revenues | 694,573,795 5.93% | 655,676,513 -77.64% | 2,932,001,440 0.07% | ||||
Cost of revenue | 527,530,631 | 708,506,983 | 1,673,064,336 | ||||
Unusual Expense (Income) | |||||||
NOPBT | 167,043,165 | (52,830,470) | 1,258,937,104 | ||||
NOPBT Margin | 24.05% | 42.94% | |||||
Operating Taxes | (121,041,419) | 29,290,121 | 333,299,788 | ||||
Tax Rate | 26.47% | ||||||
NOPAT | 288,084,583 | (82,120,590) | 925,637,316 | ||||
Net income | (98,410,898) -78.96% | (467,711,537) -151.32% | 911,362,364 -16.27% | ||||
Dividends | (38,066) | (29,549,598) | (198,735,120) | ||||
Dividend yield | 0.00% | 2.33% | 6.51% | ||||
Proceeds from repurchase of equity | (18,425,386) | 227,604,471 | 2,383,016 | ||||
BB yield | 1.47% | -17.95% | -0.08% | ||||
| Debt | |||||||
Debt current | 7,093,301 | 136,420,355 | 13,057,235 | ||||
Long-term debt | 619,596,428 | 480,265,305 | 35,917,554 | ||||
Deferred revenue | 70,477 | 60,575 | |||||
Other long-term liabilities | 52,970,999 | 21,738,951 | 6,427,929 | ||||
Net debt | 194,699,115 | (153,207,194) | (1,898,462,608) | ||||
| Cash flow | |||||||
Cash from operating activities | 156,526,985 | (242,318,513) | 890,233,363 | ||||
CAPEX | (78,783,230) | (142,565,918) | (300,451,246) | ||||
Cash from investing activities | (338,926,290) | (1,912,528,505) | 358,519,312 | ||||
Cash from financing activities | (146,265,615) | 769,762,101 | (225,736,837) | ||||
FCF | 272,528,194 | (230,864,896) | 500,758,618 | ||||
| Balance | |||||||
Cash | 467,749,505 | 557,717,346 | 2,069,971,206 | ||||
Long term investments | (35,758,890) | 212,175,508 | (122,533,808) | ||||
Excess cash | 397,261,925 | 737,109,028 | 1,800,837,326 | ||||
Stockholders' equity | 1,858,167,842 | 1,983,073,406 | 2,448,188,180 | ||||
Invested Capital | 3,185,630,694 | 2,720,190,396 | 985,850,148 | ||||
ROIC | 9.76% | 89.89% | |||||
ROCE | 4.49% | 45.18% | |||||
| EV | |||||||
Common stock shares outstanding | 122,305 | 110,860 | 101,299 | ||||
Price | 10,280.00 -10.14% | 11,440.00 -62.06% | 30,150.00 -46.06% | ||||
Market cap | 1,257,295,760 -0.86% | 1,268,234,568 -58.48% | 3,054,162,709 -43.98% | ||||
EV | 1,460,941,558 | 1,122,914,024 | 1,158,179,984 | ||||
EBITDA | 308,736,831 | 84,710,730 | 1,299,757,005 | ||||
EV/EBITDA | 4.73 | 13.26 | 0.89 | ||||
Interest | 68,588,780 | 49,227,537 | 994,059 | ||||
Interest/NOPBT | 41.06% | 0.08% | |||||